Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1762 - Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients

Date

11 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Cancer Diagnostics;  Translational Research;  Breast Cancer

Presenters

Kazutaka Otsuji

Citation

Annals of Oncology (2017) 28 (suppl_5): v449-v452. 10.1093/annonc/mdx378

Authors

K. Otsuji1, T. Sasaki2, A. Tanaka2, A. Kunita2, M. Ikemura2, K. Matsusaka3, K. Tada1, M. Fukayama2, Y. Seto4

Author affiliations

  • 1 Department Of Breast And Endocrine Surgery, Faculty Of Medicine, The University of Tokyo, 113-8655 - Tokyo/JP
  • 2 Department Of Pathology, Faculty Of Medicine, The University of Tokyo, 113-8655 - Tokyo/JP
  • 3 Department Of Molecular Oncology, Graduate School Of Medicine, Chiba University, 260-8670 - Chiba/JP
  • 4 Department Of Stomach And Esophageal Surgery, Faculty Of Medicine, The University of Tokyo, 113-8655 - Tokyo/JP
More

Resources

Abstract 1762

Background

Digital polymerase chain reaction (dPCR) has been used to yield an absolute measure of nucleic acid concentrations. Recently, a new method referred to as droplet digital PCR (ddPCR) has gained attention as a more precise and less subjective assay to quantify DNA amplification. We demonstrated the usefulness of ddPCR to determine HER2 gene amplification of breast cancer.

Methods

In this study, we used ddPCR to measure the HER2 gene copy number in clinical formalin-fixed paraffin-embedded samples of 41 primary breast cancer patients. To improve the accuracy of ddPCR analysis, we also estimated the tumour content ratio (TCR), the ratio of tumour cell count per section, for each sample.

Results

Our determination method for HER2 gene amplification using the ddPCR ratio (ERBB2:ch17cent copy number ratio) combined with the TCR showed high consistency with the conventionally defined HER2 gene status according to ASCO-CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines (P 

Conclusions

The introduction of ddPCR to determine the HER2 gene status in breast cancer is feasible for use in clinical practice and might complement or even replace conventional methods of examination in the future.

Clinical trial identification

Legal entity responsible for the study

The University of Tokyo

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.